On June 14, 2014, Calmare Therapeutics Incorporated reported the preliminary tally of consents by shareholders with respect to a recent consent solicitation neither supported by Calmare's officers nor by 4 of its 5 directors. The Company reported that preliminary tally indicates that none of the proposals were adopted because none of them received approval of a majority of the shares outstanding on the February 13, 2018 record date. The Company added that the consent solicitation for these proposals was opposed by current management, and also opposed by 4 of the 5 current directors of Calmare. The six proposals - proposed to remove 4 of the 5 current directors, elect new directors to the Board, make 2 different amendments to Calmare's existing Bylaws, and provide new requirements for additional Bylaws and Bylaw amendments were not approved.